Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

CU Niemann, MD Levin, J Dubois, S Kersting, L Enggaard, GJ Veldhuis, R Mous, CH Mellink, JA Dobber, CB Poulsen, H Frederiksen, A Janssens, I Schjødt, E C Dompeling, J Ranti, M Mattsson, M Bellido, HTT Tran, Kazem Nasserinejad, AP Kater

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
Original languageEnglish
Pages (from-to)1117-1120
Number of pages4
JournalBlood
Volume137
Issue number8
DOIs
Publication statusPublished - 25 Feb 2021

Bibliographical note

Funding Information:
The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript.

Funding Information:
The authors thank all participating patients, local data managers for study coordination and patient data collection, local investigators, and, in particular, the study team at the HOVON Data Center at the Erasmus MC Cancer Institute and the 2 central laboratories at Amsterdam UMC and Rigshospitalet. The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. The investigators are independent data owners with unrestricted publication rights.

Funding Information:
Conflict-of-interest disclosure: A.P.K. received research funding and consultancy fees from AbbVie and Janssen and a speaker's fee from AbbVie. J.D. received research funding from AbbVie. C.U.N. received research funding from the Novo Nordisk Foundation (grant NNF16OC0019302) and research support, consultancy fees, and/or travel grants from AbbVie, Gilead, Janssen, Roche, CSL Behring, Genmab, Sunesis, and Acerta/Astra Zeneca outside of this work. M.-D.L. received travel support and consultancy fees from AbbVie, Janssen, and Roche. S.K. received travel support from Cellgene. H.F. received research funding from Novartis, Alexion, Gilead, and AbbVie outside of this work. H.T.T.T. received consultancy fees from AbbVie, Pfizer, and Janssen; speaker's fees from Novartis and Janssen; and research funding from CSL Behring. The remaining authors declare no competing financial interests.

Cite this